Department of Chemistry. University of York, York, United Kingdom.
Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.
PLoS Biol. 2022 Sep 21;20(9):e3001764. doi: 10.1371/journal.pbio.3001764. eCollection 2022 Sep.
Primary familial brain calcification (PFBC) is characterised by abnormal deposits of calcium phosphate within various regions of the brain that are associated with severe cognitive impairments, psychiatric conditions, and movement disorders. Recent studies in diverse populations have shown a link between mutations in myogenesis-regulating glycosidase (MYORG) and the development of this disease. MYORG is a member of glycoside hydrolase (GH) family 31 (GH31) and, like the other mammalian GH31 enzyme α-glucosidase II, this enzyme is found in the lumen of the endoplasmic reticulum (ER). Though presumed to act as an α-glucosidase due to its localization and sequence relatedness to α-glucosidase II, MYORG has never been shown to exhibit catalytic activity. Here, we show that MYORG is an α-galactosidase and present the high-resolution crystal structure of MYORG in complex with substrate and inhibitor. Using these structures, we map detrimental mutations that are associated with MYORG-associated brain calcification and define how these mutations may drive disease progression through loss of enzymatic activity. Finally, we also detail the thermal stabilisation of MYORG afforded by a clinically approved small molecule ligand, opening the possibility of using pharmacological chaperones to enhance the activity of mutant forms of MYORG.
原发性家族性脑钙化为钙磷酸盐在脑内不同区域的异常沉积,与严重的认知障碍、精神疾病和运动障碍有关。最近在不同人群中的研究表明,肌生成调节糖苷酶(MYORG)的突变与这种疾病的发展有关。MYORG 是糖苷水解酶(GH)家族 31(GH31)的成员,与其他哺乳动物 GH31 酶 α-葡糖苷酶 II 一样,这种酶存在于内质网(ER)的腔中。尽管由于其定位和与 α-葡糖苷酶 II 的序列相似性,MYORG 被假定为具有 α-葡糖苷酶活性,但从未显示出其具有催化活性。在这里,我们证明 MYORG 是一种 α-半乳糖苷酶,并展示了 MYORG 与底物和抑制剂复合物的高分辨率晶体结构。利用这些结构,我们绘制了与 MYORG 相关的脑钙化相关的有害突变,并定义了这些突变如何通过丧失酶活性来驱动疾病进展。最后,我们还详细介绍了一种临床批准的小分子配体对 MYORG 的热稳定性的影响,为增强 MYORG 突变体的活性提供了使用药理学伴侣的可能性。